Author:
Schayowitz A,Sabnis G,Goloubeva O,Njar V C O,Brodie A M H
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, Morel L (2004) Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 279: 14579–14586
2. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O′Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252–261
3. Buckle GC, Werner L, Oh WK, Bubley G, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff P, Taplin M (2010) Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC). J Clin Oncol 28 (suppl): 7s, abstract 4660
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39
5. Cinar B, De Benedetti A, Freeman MR (2005) Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin. Cancer Res 65: 2547–2553
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献